668P Clinical factors that are prognostic for survival outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223

MLA

A. Zlotta, et al. “668P Clinical Factors That Are Prognostic for Survival Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer (MCRPC) Treated with Radium-223.” Annals of Oncology, vol. 31, Sept. 2020, pp. S537–38. EBSCOhost, https://doi.org/10.1016/j.annonc.2020.08.927.

APA

A. Zlotta, Robert J. Hamilton, Srikala S. Sridhar, Padraig Warde, Husam Alqaisi, Charles Catton, Nazanin Fallah-Rad, Adrian G. Sacher, Aaron R. Hansen, Neil Fleshner, Di Maria Jiang, Esmail Mutahar Al-Ezzi, & Marco A. J. Iafolla. (2020). 668P Clinical factors that are prognostic for survival outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223. Annals of Oncology, 31, S537–S538. https://doi.org/10.1016/j.annonc.2020.08.927

Chicago

A. Zlotta, Robert J. Hamilton, Srikala S. Sridhar, Padraig Warde, Husam Alqaisi, Charles Catton, Nazanin Fallah-Rad, et al. 2020. “668P Clinical Factors That Are Prognostic for Survival Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer (MCRPC) Treated with Radium-223.” Annals of Oncology 31 (September): S537–38. doi:10.1016/j.annonc.2020.08.927.